key: cord-0756932-tw8gjlfy
authors: Borger, Angela L.
title: Annual Convention in the Time of COVID
date: 2021-01-18
journal: J Dermatol Nurses Assoc
DOI: 10.1097/jdn.0000000000000597
sha: 87f0598d003664d820e149f794afaa077a3b3f15
doc_id: 756932
cord_uid: tw8gjlfy

nan

L ike many of you, I was disappointed that we were not able to gather together as dermatology nurses this past summer. As the COVID-19 pandemic continued, it became apparent to all involved that it was necessary and critical to move the Dermatology Nurses' Association (DNA) annual meeting to an online event. And in retrospect, that decision, however difficult to initially make, was the absolutely correct one. Regardless, however, it still made me sad we did not all get to see friends and colleagues like we do each year. I wrote in an editorial last year about how much I personally value and cherish the annual DNA meeting, both for its educational aspect and it offering the venue for welcomed, ongoing friendships. These friendships have been a highlight of my DNA membership, and I venture that is true for many of you as well.

That being said, I am here to celebrate the fantastic event the 2020 annual DNA convention turned out to be! I found the lectures to be engaging and appropriate, well researched, and clinically applicable. The speakers, who did not have the luxury of audience feedback, were professional and passionate. For long-time readers, many of you may remember that, each year, I share the notes I take at each convention. This year is no different; I diligently listened to each lecture, within the intention to share what I learned with you, our dear DNA members and readers of the journal. As always, I have tried to take these notes with attention to accuracy, but if you see a mistake or think I misunderstood a lecture point, please feel free to question the statement. It might be a good discussion and learning point for all of us! Below is the list of items I noted during my participation in the 2020 Annual DNA Convention.

• Because of changing demographics, we will encounter more patients with skin of color in our practices. • The structure and function of the skin in all races are the same with a few differences: pigmentation, hair structure, skin aging, and fibrosis. • There are differences in predisposition to particular skin diseases and differences in clinical presentation. • Regardless of skin pigmentation, the numbers of melanocytes is generally constant; what differs is the amount and distribution of melanin in the melanocytes. • This process is regulated by melanosomes: their number, size, composition, and distribution. • Melanocytes live in the basal layer of the skin. These are the growing cells of the skin and are more susceptible to DNA changes from ultraviolet (UV) light. • The main role of melanin is to absorb UV light and provide photoprotection. • A person with dark skin has a natural sun protection factor of about 13. • There are two main types of melanin:

ο Eumelanin, which is seen in all skin types but most abundant in dark skin; this is found in gray, black, blond, and brown hair, but not in red hair. ο Pheomelanin, which is found in all skin types but more abundant in people with red hair.

• Women have more pheomelanin than men; this is seen especially in the lips and nipples. • When exposed to UV light, pheomelanin produces carcinogenic oxygen-free radicals to a greater degree than eumelanin. • So, people with fair skin not only do not have as much melanin to photo-protect them, but the melanin they do have is carcinogenic. • Up to 5 times as much UV light reaches the upper dermis of white skin compared with black skin. • In black skin, there is greater UV-induced apoptosis to remove precancerous cells than in white skin.

• Melanin is a double-edged sword: It is photoprotective, but it also can actually become cancerous. The benefits of darker pigmentation include melanin distributed throughout the epidermis, including the upper layers; being an efficient UV filter; and UV-damaged cells being more efficiently removed in dark skin, which reduces the risk of skin cancers.

• What are the concerns of having darker skin pigmentation: Because melanin blocks UV light, those with darker skin are more likely to be Vitamin D deficient, more at risk for postinflammatory hyperpigmentation (PIH), and more likely to have photodermatoses; pigment disorders are more common and/or more visible; and pigment can change the clinical presentation of skin diseases, which might make diagnoses more difficult. • Sunlight can worsen PIH.

• With PIH, visible light (i.e., fluorescent lights) can possibly make pigmentation worse. • Iron-oxide sunscreens block visible light. These sunscreens are usually tinted. • Retinoids, when used properly, can help with treatment of PIH; can consider chemical peels, kojic acid 4% (over the counter), and arbutin (over the counter). • Providers can try a compounding formula for PIH: hydroquinone 6% + tretinoin 0.0125% + dexamethasone 0.1% (recipe from Dr. Amit Pandya). • Actinic prurigo is an immune-mediated photodermatitis that is particularly common in Native Americans, especially those with mixed American Indian and European ancestry. It has autosomal dominant inheritance. • Actinic prurigo usually presents with itchy, crusted papules, nodules, or plaques on sun-exposed skin. This often has lower lip and conjunctival involvement. • Polymorphous light eruption is the most common photodermatoses in skin of color. Chronic actinic dermatitis is the second most common. • Solar urticaria is more common in white skin.

• One may see calcium channel blocker-associated photodistributed hyperpigmentation, for example, on posterior necks. • Sunburns are more commonly reported among Native Americans than any other non-White racial group. • Native American ancestry is a risk factor for photosensitivity in patients with HIV. • You will not know if someone is Native American if you do not ask. • Fitzpatrick skin type does not always correlate with race or ethnicity. • Before you determine someone's Fitzpatrick skin type, you must ask them their skin reaction to sun. Do not assume someone's race or ethnicity based on appearance. • Melasma can worsen under fluorescent light. • Using hydroquinone can cause exogenous ochronosis (permanent darkening in a treated area), but this is more likely with long-term use and high concentrations.

• Ask patients where they are getting their hydroquinone and ask them to bring the container to the next office visit. You want to see what they are actually using because they may not be getting the prescription version and may be getting the product from other sources and it may have other active ingredients. • Encourage patients to not use hydroquinone products if there is not a strength listed because of concerns about exogenous ochronosis. • Many laser options for melasma treatment have not yet been optimized for skin of color. Use caution when considering use of a laser in skin of color. • Consider use of oral tranexamic acid in the adjuvant treatment of melasma, but this medication is a procoagulant, so choose patients carefully. • Calcium channel blockers and hydroxychloroquine are medications that can provoke drug-induced hyperpigmentation. • Lichen planus pigmentosus has been associated with frontal fibrosis alopecia (lichen planopilaris). • When trying to assess for redness of rosacea in a person with skin of color, consider taking a photo; sometimes, it is easier to see redness in a picture. Sometimes, having a blue background in the photo is also helpful. • Perifollicular erythema along the hairline is a classic feature of frontal fibrosing alopecia. • Certain diseases have an increased prevalence or worse prognosis in patients with pigmented skin, including acne keloidalis nuchae, central centrifugal cicatricial alopecia, cutaneous and systemic lupus, hidradenitis suppurativa (HP), keloids, mycosis fungoides, some photodermatoses, pseudofolliculitis barbae, sarcoidosis, scleroderma, traction alopecia, and vitiligo. • Consider having a patient stop use of tretinoin a week or two before chemical peels. Patients can continue hydroquinone before chemical peel. • For pregnant patients with melasma, consider azaleic acid (Pregnancy Category B) as a treatment option. • Janus kinase inhibitors for vitiligo are being studied.

• More than 7 million Americans have psoriasis, which is an autoimmune condition. • Thirty percent of people with psoriasis will develop psoriatic arthritis. • People with psoriasis are at an increased risk for cardiovascular disease and developing hypertension early in life. In addition, these patients are at an increased risk for heart attacks, peripheral vascular disease and strokes, metabolic disease, obesity, nonalcoholic fatty liver disease, alcoholism and drug use, depression, anxiety, chronic renal disease because of inflammatory renal disease, pathological inflammation of brain tissue, suicidal ideation, Crohn's disease and inflammatory bowel disease (IBD), uveitis, Hashimoto's thyroiditis, acid reflux, and sleep apnea. • Screen and treat early; consider prevention efforts for all of these comorbidities. • Consider asking the patient: What is your psoriasis keeping you from doing? • Psoriatic nail changes are associated with psoriatic arthritis.

• National Psoriasis Foundation Treat to Target Recommendations: Reduce a patient's psoriasis to 1% body surface area (BSA) or less within 3 months of initiating treatment. Acceptable response: psoriasis covers 3% BSA or less, or the patient has experienced 75% improvement in BSA. • New paradigm for psoriasis treatment: If a patient has 1%-3% of BSA affected, it is okay to use topicals, but if 3% BSA or more affected or sensitive areas, recommend use of systemic medications, sometimes along with topical treatment. • Considerations for selecting psoriasis treatments: treat to target, consider the impact of the disease on the patient's quality of life, consider the BSA affected and location, consider the patient comorbidities and risk factors, consider patient preferences, and consider the patient's financial realities. • Factors that can influence treatment decisions: past treatment experiences, past provider experiences, direct-toconsumer advertising, family/friend experiences and advice, insurance/financial resources, lifestyle, treatment vehicles and method of delivery, and monitoring parameters. • Systemic therapy should be considered for patients with psoriasis on the palms, soles, head and neck, or genitalia, or when 5% or more of BSA is involved. Biologics should be considered among the first-line treatment options in a patient who is a candidate for systemic therapy. • What are biologics? Biologics (biologic response modifiers) are protein-based drugs that target specific inflammatory immune mediators. They are derived from biologic synthesis using living cells and are large molecules. • Psoriasis is a T-cell-mediated disease.

• Tuberculosis (TB) testing is required for all biologic agents at baseline, and some require annual retesting as well. Check for Hepatitis B at baseline for tumor necrosis factor (TNF) inhibitors. • Certolizumab is favorable in pregnancy and has little crossover to placenta. • Use of Interleukin (IL)-17 medications can be associated with new-onset cases of IBD or exacerbation of preexisting IBD. • Discuss with your patients that current biologic therapy offers the promise of decreasing risk of major adverse cardiac events. • IL-23 and IL-17 are the most efficacious biologics for clearing psoriasis. • Ustekinumab has the best long-term safety record for any psoriasis biologic medication.

• Patients should not take live vaccinations while on biologic therapy.

• Drug-induced hypersensitivity syndrome (DIHS) or drug reaction with eosinophilia and systemic symptoms; fever and rashthink: severe cutaneous drug reaction; usually, fever precedes rash. Facial edema is seen early in presentation. • DIHS is a severe, cutaneous drug eruption with systemic symptoms. The kidneys and liver can be affected, causing hepatic and/or renal failure. Cardiac involvement is commonly missed and can lead to rapid mortality. • Signs and symptoms of DIHS may persist and recur for many weeks, even after stopping of the offending medication. • With drug reaction with eosinophilia and systemic symptoms, eosinophilia only occurs in 50% of the cases. • DIHS mostly occurs to a medication that has been used for a long time (2-6 weeks), especially if there is acute kidney injury that could precipitate problems. • Signs and symptoms of DIHS persist over many weeks.

• Over the next few months after presentation of DIHS, transient hypothyroidism can develop. • DIHS fatality rate can be 10%-30%, especially if undiagnosed. • DIHS can be associated with myocarditis.

• If a patient develops acute necrotizing eosinophilic myocarditis, the patient may have symptoms of acute myocardial infarction. These patients often deteriorate rapidly and have a 3-to 4-day survival. • Medications that can commonly cause DIHS include allopurinol, anticonvulsants, antibiotics (especially sulfa and minocycline), anti-TB medications, nonsteroidal anti-inflammatory drugs, and HIV drugs. • For a drug history, remember the seven "Is": medications that are instilled, inhaled, ingested, inserted, injected, incognito, and intermittent. • For those with a drug reaction, it can be helpful to establish a drug timeline. • Acute generalized exanthematous pustulosis (AGEP): A patient will be ill-appearing and having a severe cutaneous adverse reaction with rapid onset. • With AGEP, fever and rash present simultaneously, usually 24-48 hours after drug initiation. AGEP is associated with pruritus and likes to favor the trunk and intertriginous areas. • AGEP is often seen with antibiotics, particularly betalactams.

• AGEP systemic complications involve the liver, kidneys, and lungs. Upon discontinuation of the offending agent, resolution occurs within a few days. • Mortality is less than 5% with AGEP.

• Erythrodermic psoriasis is a dermatology emergency.

• Erythroderma is also called exfoliative dermatitis. This is defined as generalized scaling and redness of the skin, affecting a large portion (>90%) of the BSA. • Erythroderma is the clinical manifestation of a variety of underlying diseases and is a potentially fatal dermatology emergency. • Erythroderma is often associated with preexisting dermatosis such as atopic dermatitis (AD), psoriasis, chronic actinic dermatitis, seborrheic dermatitis, pityriasis rubra pilaris, and allergic contact dermatitis. However, this can also be seen with drug eruptions and malignancy and can be idiopathic. • Erythroderma can be acute or evolve slowly over months to years. • Use of beta-blockers can potentially exacerbate psoriasis.

• Staphylococcal scalded skin syndrome (SSSS) presents with skin tenderness and widespread erosions. This is more common in children but is also seen in adults. • In adults, renal failure is the most common underlying cofactor for SSSS, although immunosuppression is a predisposing factor too. • SSSS mortality is >60% in adults. In children, mortality rate is 4%. • SSSS presents with burning skin, not itching, and will have a positive Nikolsky sign. • With SSSS, oral-genital mucosal involvement is absent.

• SSSS heals without scarring.

• Steven-Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN) are acute life-threatening mucocutaneous reactions. • SJS/TEN usually begins 1-3 weeks after starting a medication. • These patients will have a prodrome of fever, headache, rhinitis, and myalgia. • SJS/TEN presents with symmetric eruptions with prominent mucosal involvement. • SJS/TEN can be caused by dozens of medications, but particularly sulfa drugs, allopurinol, and anticonvulsants. • In SJS/TEN, a large percentage of patients with ocular involvement will have permanent ocular sequelae, even blindness. • Secondary infections are the most common cause of death in patients with SJS/TEN. • The following are features you may see with a complicated drug eruption: fever, facial swelling, lymphadenopathy, bullous or pustular lesions, positive Nikolsky sign, mucosal involvement, systemic symptoms, and laboratory abnormalities.

• Men do not get cellulite. Women are the only ones who get cellulite because of structure of the fibrous bands that hold down the fat molecules.

• Oxymetazoline hydrochloride, a 0.1% ophthalmic solution, is approved for treatment of blepharoptosis. • Topical minocycline is available-2% gel with ethanol and 4% foam. • Topical retinoids in acne are to help with the prevention and treatment of scarring. • Use of beta-blockers for pyogenic granuloma has been investigated, with good results. • The Food and Drug Administration (FDA) has plans for new guidelines for sunscreens by the end of 2020. • At this point, the FDA says that only zinc oxide and titanium dioxide have a designation as being generally recognized as safe and effective sunscreens. • Do cannabinoids have a role in dermatology? Well, the endocannabinoid receptor system has some regulation of skin function-normalizes skin growth, decreases oil production, and reduces inflammation. There are drugs in clinical trials looking at these. • Biosimilar medication market is increasing.

• Dupilimab is now approved for patients 6 years and older. • Janus kinase inhibitors are being investigated for use in many dermatology conditions including alopecia areata, AD, vitiligo, and psoriasis. • Avoid TNF inhibitors in patients with congestive heart failure. • Overweight patients are less likely to respond to TNF inhibitors.

• This presentation discussed transgender care and genderaffirming care as well as nonbinary care. • There is no one way to be transgender or nonbinary.

• There is no one way to look transgender. • Health disparities in the transgender community are common. • What are aspects of affirming care? Language, knowledge, clinic environment, and documentation and policy. ο Language: Are we addressing patients using their preferred name or pronoun? Do we have the ability to use gender-neutral language and gender-neutral terms? ο Knowledge: clinical and nonclinical. ο Clinic environment: Are the clinic space, marketing material, handouts, and bathroom access welcoming to LGTBQ patients? ο Documentation and policy: What do your forms ask? Do they ask for pronouns? What policies are in place to affirm to patients that your practice is friendly?

• Sexual orientation does not equal gender identity.

• Celebrate the language people use to identify themselves.

• Terminology can include sexual orientation, sex assigned at birth, gender identify, and gender expression.

• It is more common for someone to be intersex than to have red hair. • There are over 100 different gender identities. • There are over 150 different sexual orientations.

• Be mindful of language. Gender-neutral language should be used. Avoid "ladies," "gentlemen," "ma'am," "sir," "girls," "guys," and so forth. Try using "folks," "friends," "everyone," "you," and "all." • Shifting to gender-inclusive language respects and acknowledges the gender identities of all people and removes assumptions. If we are not gendering someone, we cannot misgender them. • Names and pronouns are important to patients. Legal names and affirming names are different. You show respect and care by calling someone by their preferred choices. • Introduce yourself to patients and colleagues using your pronouns. Build pronouns into your introductions. My pronouns are she/her/hers. You can ask: "What pronouns do you use?" or "What are your pronouns?" • Consider confidentiality issues. For example, some patients may prefer a different pronoun when they are in the examination room alone versus when their parents may be present. Be sure to confirm their preferences so you do not accidently out someone. • You will make a mistake with mispronouning someone. When this happens, apologize, correct yourself, and move on. Furthermore, you can pause at the end of a visit to check in and have a relational moment to confirm the patient has a better interaction with healthcare. • You need to create a system for accountability of using proper pronouns and to do better. Consider pronoun practice-practicewithpronouns.com or MyPronouns.org. • Create an environment that is accountable. Must be able to politely correct your colleagues. A call-in culture, not a call-out culture. Be an advocate for a just culture while giving colleagues the benefit of the doubt. We are building a system of accountability. • Examination considerations in dermatology: addressing identity, that is, only asking what is required; look at language use with the patient, that is, affirming names and pronouns as well as body parts; documentation using affirming names, pronouns, and body parts; confidentiality of identity; ask about use of gender-affirming tools, namely, chest binders and tucking. • Documentation: having both a legal name and a preferred name in electronic medical records. • Identity is personal and can never be assumed. • Hair loss can be categorized as problems with hair follicle pathology, disturbances in hair cycling, or hair shaft dystrophies. • Hair loss can be socially and psychologically distressing for many women. • Hair follicles display intermittent activity.

• There is a large influence of hormones on hair loss in women. • Antiandrogens and androgen inhibitors can reverse the biologic effects of androgens at the cutaneous level. • Not all women with hair loss will show excess androgen levels; often, androgen levels will be normal in these patients. • In women who have female pattern hair loss (FPHL) and androgen excess, most of these patients will show no other clinical signs or biochemical evidence of androgen excess. • FPHL is more common with increasing age.

• It is normal to lose 50-100 hairs per day.

• Consider a more in-depth endocrine evaluation if hair loss is associated with sudden onset, rapid progression, menstrual abnormalities, hirsutism, or reactivation of acne. • In FPHL, one would expect 99% of hairs lost to be telogen. • Although the benefit may be limited, in FPHL, we can consider evaluation of thyroid-stimulating hormone, free T3, free T4, DHEA-S, free testosterone, total testosterone, sex-hormone-binding globulin, ferritin, hemoglobin, iron, total iron binding, iron saturation, and Vitamin D. • FPHL is different than male pattern hair loss; the mechanism is not clear. • Treatments for FPHL include topical minoxidil, systemic or topical spironolactone, and systemic finasteride. • Procedures for FPHL: platelet-rich plasma, which contains growth factors; the patient's own platelet-rich plasma is injected into the scalp.

• HS is a chronic, debilitating inflammatory disorder of the hair follicle. • The follicle is the primary source of the HS problem.

• HS has a female predominance, and the highest prevalence is among 30-to 39-year-old patients. • There is higher prevalence of HS in Black patients.

• HS is associated with obesity, tobacco use, and low socioeconomic status. • HS is associated with follicular occlusion, although we are not completely sure what causes this. • There is a genetic component to some forms of HS.

• HS often has "double comedones"-two side-by-side comedones. • There are different subtypes of HS:

ο Axillary-mammary-inguinal subtype-Patients get lesions to the front of the body; patients tend to be obese. ο Follicular subtype-This is more common in men, and lesions tend to be on the trunk and thighs; patients with this subtype tend to be smokers. This subtype is difficult to treat; many comedones to face. This is the subtype more likely to be affected by genetic defects. ο Gluteal subtype-usually in young, thin men with HS in the buttock and, maybe, inguinal fold; with severe symptoms. Patients with this subtype are at risk of developing a squamous cell carcinoma (SCC) in the HS lesion. ο Syndromic subtype-Patients with this subtype have HS plus another inflammatory disorder; their HS tends to not be as severe as the other subtypes.

• HS has many comorbidities: lymphatic obstruction, IBD such as Crohn's disease or ulcerative colitis, cardiovascular disease, metabolic disease, SCC, and depression. • Patients with HS have worse quality-of-life scores than do patients who have psoriasis. • The strongest association between Crohn's and HS can be found in men, those 45-64 years old, nonobese patients, and nonsmokers. • If a patient has a "knife-cut" sign, this may be a sign of cutaneous Crohn's; consider a biopsy of this area. • Lesions of Crohn's can mimic HS.

• The SCCs associated with HS are more likely to metastasize, and there is higher mortality associated with SCCs in the context of HS. • HS treatments need to be individualized.

• HS treatment goals may be lesion control, wound care, odor control, and pain management, among other concerns. • HS treatment principles: individualize to the patient, consider comorbidities, consider cost, treat the whole patient, and layer and rotate therapies. • Consider referrals for psychosocial support, nutrition, wound care, and surgery. • Monotherapy for HS is less likely to be effective.

• Neodymium-doped yttrium aluminum garnet laser is a good treatment for mild-to-moderate HS. • Surgical options:

ο Incision and drainage are usually discouraged because of high recurrence rate. ο Can consider intralesional injection of steroids for acutely inflamed, painful HS lesions.

• Deroofing or marsupialization of smaller lesions: removing the roof of the sinus tract and leaving them open. • Metformin decreases androgens.

• Lactic acidosis is a concerning side effect that can be seen with metformin. • Avoid metformin in patients with liver disease, heart failure, or alcoholism. • Metformin is Pregnancy Category B.

• Finasteride can be used in the treatment of HS, even in pediatric patients. • Finasteride is Pregnancy Category X.

• Check a prostate-specific antigen (PSA) in men before starting finasteride therapy. • Spironolactone is an antiandrogen.

• There is not an increased risk of human cancers with use of spironolactone. • Diet and weight loss for the management of HS are important for some patients. • In general, a balanced diet with fewer carbohydrates and more lean proteins is more beneficial for HS. Avoid sugar-sweetened beverages. • Milk contains androgens. Milk intake can flare HS in some patients. • In some patients, HS can improve after bariatric surgery.

• Pemphigus vulgaris (PV) and pemphigoid are autoimmune blistering disorders. • Direct immunofluorescence testing is helpful in the evaluation of pemphigus and pemphigoid. • A deep shave biopsy is generally preferred over a punch for diagnosis. • Indirect immunofluorescence looks at serum.

• PV: binding of autoantibodies to the surface of epidermal cells, which leads to acantholysis. • PV: commonly begins in middle age, with oral lesions.

• Desquamative gingivitis is seen in PV, mucous membrane pemphigoid, and oral erosive lichen planus. • Scalp involvement is common in PV. Esophageal involvement is not common in PV. • Patients with pemphigus foliaceus do not have mucosal involvement. • Oral care is very important in patients with blister diseases. They should maintain the best oral hygiene that they can and consider more frequent dental cleanings if possible. • Use of prednisone is common in PV. May need to be on prednisone for a few weeks and continue until no new lesions have developed for 1-2 weeks and older lesions are healing well. Prednisone taper should be slow-may take up to a year. • Steroid-sparing agents involved in the treatment of PV include azathioprine, mycophenolate mofetil, dapsone, doxycycline/minocycline, cyclophosphamide, methotrexate, and cyclosporine.

• Using these steroid-sparing agents does not decrease time to remission but does decrease rate of relapse. • Rituximab is a good treatment option for PV.

• Bullous pemphigoid (BP): binding of autoantibodies between the basal cells of the epidermis and the basement membrane zone. • BP is the most common autoimmune bullous disorder.

• BP is associated with significant pruritus and is primarily seen in elderly patients (>70 years old). • Rate of survival for patients with BP is less than that for age-matched controls. • Ten to thirty percent of patients with BP have oral mucosal involvement. • Trauma-induced pemphigoid: can occur at sites of previous radiation, in sunburned areas, stomal areas, and postsurgical areas. • Some drugs may induce BP.

• BP is more common in patients with neurologic disease: dementia, Parkinson's disease, stroke, bipolar disease, and multiple sclerosis. • In addition, neurologic disease is more likely to occur in patients with BP than in age-matched controls. • Pearl: If you have a patient with excoriated, prurigolike, erythematous papular, eczematous, and urticarial lesions without obvious blistering, this may represent the only manifestations of BP for months or years and is known as "nonbullous pemphigoid." In this case, the development of severe pruritus/excoriations in an elderly patient, particularly with a neurologic disorder, should trigger an evaluation for BP. • Doxycycline, prednisone, and methotrexate are good treatment choices for BP, although there are other medications.

• High-risk oral medications include prednisone, methotrexate, mycophenolate mofetil, cyclosporine, acitretin, dapsone, and hydroxychloroquine. • Concerning effects can include hepatotoxicity, hematologic toxicity, infection risk, teratogenicity/gonadotoxicity, metabolic effects, and effects on the lung, kidney, and brain. • Hepatotoxicity: can be affected by patient profile factors such as habits, nutrition, underlying medical history, concomitant drug use, and demographics. • Increased risk for infections such as Hepatitis B, Hepatitis C, TB, HIV, Strongyloides stercoralis, pneumocystis pneumonia, influenza, herpes zoster, and pneumococcal pneumonia. • Vaccinations with high-risk oral medications: Live vaccinations are safe to give 13-30 days before immunomodulatory therapy or (conservatively) 3 months after cessation of therapy (1 month for prednisone); inactivated vaccines are safe while on immunomodulatory therapy, but the therapeutic response may be compromised.

• Seasonal influenza vaccination is a nonlive vaccine and is okay to use, but avoid the intranasal vaccine because this is a live vaccine. The pneumococcal vaccine is a nonlive vaccine and is safe. The new shingles vaccination (recombinant zoster vaccine) is okay to use, but the older live attenuated zoster vaccine should be used before starting immunosuppressive therapy. • Baseline evaluation for long-term prednisone use: complete blood count, comprehensive metabolic panel, and lipids; consider hemoglobin A1C; screen for Hepatitis B/Hepatitis C, TB, and HIV; consider vaccinations; consider baseline dual-energy x-ray absorptiometry scan especially in postmenopausal women and men > 50 years old; consider pneumocystis pneumonia prophylaxis. • When using prednisone therapy, loss of bone mineral density occurs mainly within the first 6 months of therapy. Bone density concerns are not something to think about months down the road. • Recommend folate supplement (1-5 mg daily) with methotrexate dosing. • Before initiation of methotrexate, consider baseline chest x-ray in high-risk patients because pulmonary toxicity/hypersensitivity pneumonitis may progress to fibrosis. • With cyclosporine, we can see renal toxicity and hypertension as well as hyperkalemia, hyperuricemia, hypomagnesemia, and hyperlipidemia. • Cyclosporine has multiple drug interactions.

• Acitretin is not immunosuppressive.

• Must avoid alcohol completely with use of acitretin-Alcohol will change the half-life of the medication from 2 days to 120 days. • Dapsone inhibits neutrophil activation. Dapsone has a number of adverse effects. • Screen for glucose-6-phosphate dehydrogenase deficiency before starting dapsone. • Dapsone can cause severe and life-threatening agranulocytosismonitor laboratories carefully and frequently, especially in the beginning. • Dapsone should be used with caution in patients with an allergy to sulfonamide antibiotics. • Hydroxychloroquine has a slow onset of action; it may take 4-6 months to achieve maximum effect. • Ocular toxicity can occur with hydroxychloroquine; be sure to get baseline eye examination within the first year of use.

• Goals of acne treatment: normalize hyperkeratinization and follicular desquamation, decrease inflammation, decrease Propionibacterium acnes, decrease sebum, and prevent scarring.

have you changed your clinical practice as a result of this educational offering? I would be interested to hear your feedback; feel free to email me with your thoughts or comments. Finally, before ending this first editorial of 2021, I want to call your attention to the pages where we celebrate our peer reviewers. The journal has a deep respect for the individuals who volunteer as our peer reviewers, and it is with excitement and thankfulness that I call your attention to the dermatology nurses and friends who have shared their expertise. Their immense contributions to the development of the articles you see within the pages of our journal are celebrated, and I ask you to join me in acknowledging their important work.

Looking forward to hearing from you, Angela L. Borger Editor-in-Chief alborger@aol.com

• Acne medications can include keratolytics, antibiotics, antibacterials, anti-inflammatories, hormones, and retinoids

• Benzoyl peroxide may bleach hair, clothes, and bed linensbe careful with use

• In fair-skinned patients, consider avoiding tretinoin because this can worsen vasodilation and presentation of erythema. Azelaic acid and adapalene would be better options for fair-skinned patients

• Clindamycin, erythromycin, and sulfa are antibiotics used topically in acne treatments

• Minocycline foam is now available

• Topical sulfa and minocycline foam should not be used in pregnancy

Avoid use of dapsone and topical benzoyl peroxide at the same time, because this can cause temporary yellow/ orange discoloration of the skin and facial hair

Systemic acne therapies often have a more rapid onset of improvement

• Patients may need combination therapy to treat their acne, and this decision is based on many factors

AD: a chronic and chronically relapsing inflammatory skin disease

• AD has a genetic predisposition

Atopic means unusualness (looking at word development)

• What is abnormal in AD? Dysfunction of skin barrier; dysfunction of T helper type 2 (Th2) cell adaptive immune responses to common environmental antigens

• Thirteen percent of children in the United States have AD. • AD is not only a disease of childhood. • Worldwide: AD affects 20%-30% of children and 3%-10% of adults

• Early-onset AD tends to improve by adulthood

• Persistence of AD into adulthood is associated with later-onset AD, more persistent AD, and severe AD

Twenty-five percent of patients with AD report adultonset disease

• Importance of an accurate diagnosis of AD: ο makes a chronic disease understandable

ο alerts provider to watch for other skin disorders seen at a higher frequency in AD

ο alerts provider to watch for other disorders associated with AD; and ο allows insurance coverage of AD medications with FDA approval

• In a meta-analysis, 78 different signs and symptoms of AD worldwide have been identified, with top rankings including pruritis, xerosis, lichenification, course influenced by emotions/environment, and flexural involvement

• Diseases associated with AD include ear infections, strep throat infections, urinary tract infections, clinical depression, osteoporosis and osteopenia, attention-deficit disorder and attention-deficit/hyperactivity disorder

• Cutaneous disorders seen in AD include cutaneous infections and allergic contact dermatitis (especially to nickel)

• AD may have physical findings

• AD treatments: topical agents, phototherapy, and systemic therapy

defined as a diminished pharmacologic response after repeated drug administration

• Millions of Americans are affected by nonhealing wounds: pressure, neuropathic, venous, and arterial

• About 10% of chronic leg wounds are considered atypical. • Understanding underlying pathophysiology is key in managing atypical wounds

Wound repair and healing: hemostasis (0-24 hours), inflammation (1-6 days), proliferation (4-24 days

Inflammation and proliferation stages can be difficult-If wound is not moving on toward remodeling stage after 30 days

• Patients may have underlying conditions including infection, malignancy, inflammatory disease, renal disease, allergic response, and trauma

Principles of wound care: control or eliminate causative factors, provide systemic support, and maintain good wound environment-not too wet

• When treating wounds, try to get the HgA1C% to 8%. • Wounds heal better when kept moist. • Prevent and manage infections in wounds. • Debridement: sharp, autolytic, and enzymatic

Use cleansers that are not cytotoxic. • Control odor and promote comfort-these are important to patients

• Wounds heal from the bottom up

• Protect surrounding skin when treating a wound

that was quite a bit of information! I think you can probably tell how much fun I had listening to each presentation. It's nice to have learning points reinforced, while learning new tricks and clinical pearls simultaneously